サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1780347

患者登録ソフトウェアの世界市場 (～2030年)：疾患 (糖尿病・がん・希少疾患・喘息・腎臓)・製品 (医薬品・デバイス)・ユースケース (集団健康・調査)・エンドユーザー (営利：製薬会社・保険者・病院)・(非営利：政府))・地域別

Patient Registry Software Market by Disease (Diabetes, Cancer, Rare, Asthma, Kidney), Product (Drugs, Device), Use Case (Population Health, Research), End User [(Profit: Pharma, Payer, Hospital), (Non-Profit: Govt)] & Region - Global Forecast to 2030

出版日
ページ情報
英文 381 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
患者登録ソフトウェアの世界市場 (～2030年)：疾患 (糖尿病・がん・希少疾患・喘息・腎臓)・製品 (医薬品・デバイス)・ユースケース (集団健康・調査)・エンドユーザー (営利：製薬会社・保険者・病院)・(非営利：政府))・地域別
出版日: 2025年07月24日
発行: MarketsandMarkets
ページ情報: 英文 381 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の患者登録ソフトウェアの市場規模は、2025年の22億5,000万米ドルから、CAGR 9.8%で推移し、2030年には36億1,000万米ドルに達すると予測されています。

医療システムは、ケアの質を向上させ、規制要件を満たすために、患者データの収集と分析にますます注力しています。患者登録ソフトウェアは、疾患、医療処置、集団に関するデータを収集し、臨床研究や集団健康管理を支援します。これらのプラットフォームは、医薬品評価やバリューベースのケアを支える実世界データの創出に不可欠であり、最終的には医療コストの削減と市場成長を促進する役割を果たしています。

調査範囲
調査対象年 2023-2030年
基準年 2024年
予測期間 2025-2030年
単位 金額（米ドル）
セグメント 製品・ユースケース・登録タイプ・導入モデル・エンドユーザー
対象地域 北米・欧州・アジア太平洋・ラテンアメリカ・中東&アフリカ
Patient Registry Software Market-IMG1

"患者直接登録セグメントが予測期間中に最も高い成長を示す見通し"

患者直接登録セグメントは、患者のエンゲージメントの向上、ePROやモバイルアプリなどのデジタルヘルスツールの普及、患者由来のRWE (リアルワールドエビデンス) への需要、患者報告アウトカムに焦点を当てた分散型臨床試験（DCT）の増加により、最も高いCAGRを記録すると予想されています。バーチャルプラットフォームによりデータ収集が簡素化され、医療従事者の負担が軽減されると同時に、長期的なフォローアップや多様な患者のリクルートが可能になります。

"ユースケース別では、医療研究・臨床研究の部門が2024年に最大のシェアを示す"

この成長は、臨床試験や医薬品開発におけるRWD (リアルワールドデータ) およびRWEの利用拡大により推進されています。患者登録ソフトウェアは構造化された縦断的データを収集し、研究者がアウトカムの分析や安全性のモニタリングを行うのに貢献します。個別化医療の進展や、ライフサイエンス企業、学術機関、公衆衛生機関との協働の拡大も、強固な登録インフラへのニーズをさらに高めています。また、分散型試験や市販後調査（PMS）へのシフトも、このセグメントの優位性を後押ししています。

"地域別では、北米が2024年に最大シェアを示す"

この背景には、堅固な規制枠組みやデジタルヘルスの早期導入があり、MRO CorpやImageTrendといった主要企業が競合と革新を促進しています。米国保健福祉省（HHS）によるデータ近代化イニシアティブや、CDCによる慢性疾患サーベイランスの強化といった連邦政府の取り組みによって、登録プラットフォームの需要が拡大しています。特に2025年2月には、VeradigmとHealthVerityが提携し、心血管および代謝疾患のデータをHealthVerityのプライバシー準拠型プラットフォームに統合することで、患者の医療経過に関する包括的研究を可能にしました。さらに2024年4月には、ESO SolutionsがLogis Solutionsを買収し、データ駆動型の救急対応を強化、相互運用性と患者アウトカムの向上を図りました。これらの動きにより、北米は患者登録ソフトウェア分野における革新とデータ統合の先導地域としての地位を確固たるものとしています。

当レポートでは、世界の患者登録ソフトウェアの市場を調査し、市場概要、市場成長への各種影響因子の分析、技術・特許の動向、法規制環境、ケーススタディ、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 市場力学
    • 市場抑制要因
    • 市場機会
    • 市場の課題
  • 顧客の事業に影響を与える動向/混乱
  • 業界動向
  • エコシステム分析
  • バリューチェーン分析
  • 技術分析
  • 規制分析
  • 価格分析
  • ポーターのファイブフォース分析
  • 特許分析
  • 主なステークホルダーと購入基準
  • エンドユーザー分析
  • 主な会議とイベント
  • ケーススタディ分析
  • 投資と資金調達のシナリオ
  • ビジネスモデル分析
  • AI/生成AIが患者登録ソフトウェア市場に与える影響
  • 2025年の米国関税が患者登録ソフトウェア市場に与える影響

第6章 患者登録ソフトウェア市場：登録タイプ別

  • 疾病登録
    • 糖尿病登録
    • 心臓血管登録
    • がん登録
    • 希少疾患登録
    • 喘息登録
    • 慢性腎疾患登録
    • 整形外科登録
    • 予防接種登録
    • 先天性異常登録
    • その他の疾患登録
  • 製品登録
    • 医療機器登録
    • 医薬品登録

第7章 患者登録ソフトウェア市場：製品別

  • 患者直接登録（患者記録登録）
  • サイトベース/臨床データ（プロバイダー記録）登録

第8章 患者登録ソフトウェア市場：ユースケース別

  • 医療研究・臨床研究
  • 品質向上
  • 患者ケア管理
  • 集団健康（ポピュレーションヘルス）
  • ポイントオブケアサポート
  • 公衆衛生サーベイランス
  • 患者のセルフケア
  • 患者エンゲージメント
  • その他

第9章 患者登録ソフトウェア市場：導入モデル別

  • オンプレミスモデル
  • クラウドベースモデル

第10章 患者登録ソフトウェア市場：エンドユーザー別

  • 営利目的の登録
    • 製薬、バイオテクノロジー、医療機器企業
    • 医療保険者
    • 医療提供者
  • 非営利目的の登録
    • 医療専門学会
    • 患者団体
  • 政府およびサードパーティ管理機関
  • その他

第11章 患者登録ソフトウェア市場：地域別

  • 北米
    • マクロ経済見通し
    • 米国
    • カナダ
  • 欧州
    • マクロ経済見通し
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • マクロ経済見通し
    • 日本
    • 中国
    • インド
    • その他
  • ラテンアメリカ
    • ラテンアメリカのマクロ経済見通し
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 中東・アフリカのマクロ経済見通し
    • GCC諸国
    • その他

第12章 競合情勢

  • 概要
  • 主要参入企業の戦略/強み
  • 収益分析
  • 市場シェア分析
  • 企業評価マトリックス：主要企業
  • 企業評価マトリックス：スタートアップ/中小企業
  • 企業評価と財務指標
  • ブランド/ソフトウェア比較
  • 競合シナリオ

第13章 企業プロファイル

  • 主要企業
    • IBM
    • IQVIA HOLDINGS INC.
    • HEALTH CATALYST, INC.
    • ORACLE
    • UNITEDHEALTH GROUP
    • CONDUENT INCORPORATED
    • ELEKTA
    • NEC CORPORATION（NEC SOFTWARE SOLUTIONS UK LIMITED）
    • DASSAULT SYSTEMES（MEDIDATA）
    • EVIDENTIQ（DACIMA SOFTWARE INC.）
    • MRO（FIGMD, INC.）
    • IMAGETREND
    • GLOBAL VISION TECHNOLOGIES, INC.
    • SYNEOS HEALTH
    • VERADIGM LLC
    • ESO
    • ORDINAL DATA INC.
    • CEDARON MEDICAL
    • FIVOS HEALTH
    • ACROSS HEALTHCARE
  • その他の企業
    • VERANA HEALTH
    • PULSE INFOFRAME INC.
    • AMPLITUDE CLINICAL OUTCOMES
    • NPHASE, INC.（REDCAP CLOUD）
    • OM1

第14章 付録

図表

List of Tables

  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 FACTOR ANALYSIS
  • TABLE 3 RISK ASSESSMENT: PATIENT REGISTRY SOFTWARE MARKET
  • TABLE 4 PATIENT REGISTRY SOFTWARE MARKET: IMPACT ANALYSIS
  • TABLE 5 HEALTHCARE DATA BREACHES IN US
  • TABLE 6 PATIENT REGISTRY SOFTWARE MARKET: ROLE IN ECOSYSTEM
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 REGULATORY SCENARIO OF NORTH AMERICA
  • TABLE 13 REGULATORY SCENARIO OF EUROPE
  • TABLE 14 REGULATORY SCENARIO OF ASIA PACIFIC
  • TABLE 15 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
  • TABLE 16 REGULATORY SCENARIO OF LATIN AMERICA
  • TABLE 17 AVERAGE COST OF PATIENT REGISTRY SOFTWARE, BY END USER (ORDINAL HEALTH INC.) (2024)
  • TABLE 18 INDICATIVE PRICE RANGE OF PATIENT REGISTRY SOFTWARE, BY REGION (2024)
  • TABLE 19 PATIENT REGISTRY SOFTWARE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR PATIENT REGISTRY SOFTWARE
  • TABLE 21 PATIENT REGISTRY SOFTWARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 24 UNMET NEEDS IN PATIENT REGISTRY SOFTWARE MARKET
  • TABLE 25 END-USER EXPECTATIONS IN PATIENT REGISTRY SOFTWARE MARKET
  • TABLE 26 PATIENT REGISTRY SOFTWARE MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 27 CASE STUDY 1: CANCER REGISTRY IMPLEMENTATION WITH DACIMA CLINICAL SUITE
  • TABLE 28 CASE STUDY 2: ENHANCING REAL-WORLD EVIDENCE WITH CASTOR RWE
  • TABLE 29 CASE STUDY 3: DEVICE DATA INTEGRATION USING MEDIREPORT 360
  • TABLE 30 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 31 PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 32 PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 33 PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 PATIENT REGISTRY SOFTWARE MARKET FOR DIABETES REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 35 PATIENT REGISTRY SOFTWARE MARKET FOR CARDIOVASCULAR REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 36 PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 37 PATIENT REGISTRY SOFTWARE MARKET FOR RARE DISEASE REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 38 PATIENT REGISTRY SOFTWARE MARKET FOR ASTHMA REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 PATIENT REGISTRY SOFTWARE MARKET FOR CHRONIC KIDNEY REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 40 PATIENT REGISTRY SOFTWARE MARKET FOR ORTHOPEDIC REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 41 PATIENT REGISTRY SOFTWARE MARKET FOR IMMUNIZATION REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 PATIENT REGISTRY SOFTWARE MARKET FOR BIRTH DEFECT REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 43 PATIENT REGISTRY SOFTWARE MARKET FOR OTHER DISEASE REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 45 PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 46 PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL DEVICE REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 PATIENT REGISTRY SOFTWARE MARKET FOR DRUG REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 48 PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 49 PATIENT REGISTRY SOFTWARE MARKET FOR DIRECT-TO-PATIENT (PATIENT-RECORDED) REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 PATIENT REGISTRY SOFTWARE MARKET FOR SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 51 PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 52 PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 53 PATIENT REGISTRY SOFTWARE MARKET FOR QUALITY IMPROVEMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 54 PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 55 PATIENT REGISTRY SOFTWARE MARKET FOR POPULATION HEALTH, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 PATIENT REGISTRY SOFTWARE MARKET FOR POINT-OF-CARE SUPPORT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT SELF-CARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 59 PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT ENGAGEMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 60 PATIENT REGISTRY SOFTWARE MARKET FOR OTHER USE CASES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 61 PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 62 PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 65 PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 66 PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 68 PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PAYERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 69 PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 70 PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 72 PATIENT REGISTRY SOFTWARE MARKET FOR CLINICS & OUTPATIENT SETTINGS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 73 PATIENT REGISTRY SOFTWARE MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 74 PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 75 PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL SPECIALTY SOCIETIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT ORGANIZATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 78 PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT & THIRD-PARTY ADMINISTRATORS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 PATIENT REGISTRY SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 80 PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 83 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 84 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 85 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 87 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 91 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 92 US: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 93 US: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 94 US: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 95 US: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 96 US: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 97 US: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 98 US: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 99 US: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 100 US: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 101 US: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 102 CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 103 CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 104 CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 105 CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 106 CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 107 CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 108 CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 109 CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 110 CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 111 CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 112 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 114 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 115 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 117 EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 118 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 119 EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 120 EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 121 EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 123 UK: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 124 UK: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 125 UK: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 126 UK: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 127 UK: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 128 UK: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 129 UK: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 130 UK: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 131 UK: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 132 UK: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 133 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 134 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 135 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 136 GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 137 GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 138 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 139 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 140 GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 141 GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 142 GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 143 FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 144 FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 145 FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 146 FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 147 FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 148 FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 149 FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 150 FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 151 FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 152 FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 153 ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 154 ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 155 ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 156 ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 157 ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 158 ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 159 ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 160 ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 161 ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 162 ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 163 SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 164 SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 165 SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 166 SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 167 SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 168 SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 169 SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 170 SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 171 SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 172 SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 173 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 174 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 175 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 176 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 177 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 178 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 179 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 180 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 181 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 182 REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 190 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 192 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 195 JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 196 JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 197 JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 199 JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 200 JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 201 JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 202 JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 203 JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 205 CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 206 CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 207 CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 208 CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 210 CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 211 CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 212 CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 213 CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 215 INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 216 INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 217 INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 219 INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 220 INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 221 INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 223 INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 224 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 225 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 226 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 229 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 230 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 231 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 232 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 233 REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 235 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 236 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 237 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 238 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 239 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 242 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 243 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 244 LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 245 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 246 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 247 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 249 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 251 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 252 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 253 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 254 BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 255 MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 256 MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 257 MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 258 MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 259 MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 260 MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 261 MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 262 MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 263 MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 264 MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 265 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 266 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 270 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 275 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 276 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 277 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 278 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 279 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 280 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 282 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 283 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 284 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 285 MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 287 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 288 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 291 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 292 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 293 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 294 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 295 GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 296 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 297 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023-2030 (USD MILLION)
  • TABLE 298 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023-2030 (USD MILLION)
  • TABLE 299 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 301 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023-2030 (USD MILLION)
  • TABLE 302 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 303 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 304 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 305 REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 306 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET, JANUARY 2022-JUNE 2025
  • TABLE 307 PATIENT REGISTRY SOFTWARE MARKET: DEGREE OF COMPETITION
  • TABLE 308 PATIENT REGISTRY SOFTWARE MARKET: REGION FOOTPRINT
  • TABLE 309 PATIENT REGISTRY SOFTWARE MARKET: PRODUCT FOOTPRINT
  • TABLE 310 PATIENT REGISTRY SOFTWARE MARKET: USE CASE FOOTPRINT
  • TABLE 311 PATIENT REGISTRY SOFTWARE MARKET: REGISTRY TYPE FOOTPRINT
  • TABLE 312 PATIENT REGISTRY SOFTWARE MARKET: DEPLOYMENT FOOTPRINT
  • TABLE 313 PATIENT REGISTRY SOFTWARE MARKET: END-USER FOOTPRINT
  • TABLE 314 PATIENT REGISTRY SOFTWARE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 315 PATIENT REGISTRY SOFTWARE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY PRODUCT AND REGION
  • TABLE 316 PATIENT REGISTRY SOFTWARE MARKET: PRODUCT LAUNCHES, APPROVALS, UPGRADES, AND ENHANCEMENTS, JANUARY 2022-JUNE 2025
  • TABLE 317 PATIENT REGISTRY SOFTWARE MARKET: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 318 PATIENT REGISTRY SOFTWARE MARKET: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 319 IBM: COMPANY OVERVIEW
  • TABLE 320 IBM: PRODUCTS OFFERED
  • TABLE 321 IBM: PRODUCT ENHANCEMENTS, JANUARY 2022-JUNE 2025
  • TABLE 322 IQVIA HOLDINGS INC.: COMPANY OVERVIEW
  • TABLE 323 IQVIA HOLDINGS INC.: PRODUCTS OFFERED
  • TABLE 324 IQVIA HOLDINGS INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 325 HEALTH CATALYST, INC.: COMPANY OVERVIEW
  • TABLE 326 HEALTH CATALYST, INC.: PRODUCTS OFFERED
  • TABLE 327 HEALTH CATALYST, INC.: PRODUCT APPROVALS, JANUARY 2022-JUNE 2025
  • TABLE 328 HEALTH CATALYST, INC.: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 329 HEALTH CATALYST, INC.: OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 330 ORACLE: COMPANY OVERVIEW
  • TABLE 331 ORACLE: PRODUCTS OFFERED
  • TABLE 332 ORACLE: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 333 UNITEDHEALTH GROUP: COMPANY OVERVIEW
  • TABLE 334 UNITEDHEALTH GROUP: PRODUCTS OFFERED
  • TABLE 335 UNITEDHEALTH GROUP: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 336 CONDUENT INCORPORATED: COMPANY OVERVIEW
  • TABLE 337 CONDUENT INCORPORATED: PRODUCTS OFFERED
  • TABLE 338 CONDUENT INCORPORATED: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 339 ELEKTA: COMPANY OVERVIEW
  • TABLE 340 ELEKTA: PRODUCTS OFFERED
  • TABLE 341 ELEKTA: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 342 NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED): COMPANY OVERVIEW
  • TABLE 343 NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED): PRODUCTS OFFERED
  • TABLE 344 DASSAULT SYSTEMES (MEDIDATA): COMPANY OVERVIEW
  • TABLE 345 DASSAULT SYSTEMES (MEDIDATA): PRODUCTS OFFERED
  • TABLE 346 DASSAULT SYSTEMES (MEDIDATA): PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
  • TABLE 347 DASSAULT SYSTEMES (MEDIDATA): DEALS, JANUARY 2022-JUNE 2025
  • TABLE 348 EVIDENTIQ (DECIMA SOFTWARE INC.): COMPANY OVERVIEW
  • TABLE 349 EVIDENTIQ (DECIMA SOFTWARE INC.): PRODUCTS OFFERED
  • TABLE 350 EVIDENTIQ (DECIMA SOFTWARE INC.): DEALS, JANUARY 2022-JUNE 2025
  • TABLE 351 MRO (FIGMD, INC.): COMPANY OVERVIEW
  • TABLE 352 MRO (FIGMD, INC.): PRODUCTS OFFERED
  • TABLE 353 MRO (FIGMD, INC.): DEALS, JANUARY 2022-JUNE 2025
  • TABLE 354 MRO (FIGMD, INC.): OTHER DEVELOPMENTS, JANUARY 2022-JUNE 2025
  • TABLE 355 IMAGETREND: COMPANY OVERVIEW
  • TABLE 356 IMAGETREND: PRODUCTS OFFERED
  • TABLE 357 IMAGETREND: PRODUCT UPGRADES, JANUARY 2022-JUNE 2025
  • TABLE 358 IMAGETREND: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 359 GLOBAL VISION TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 360 GLOBAL VISION TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 361 GLOBAL VISION TECHNOLOGIES, INC.: OTHER DEVELOPMENTS , JANUARY 2022-JUNE 2025
  • TABLE 362 SYNEOS HEALTH: COMPANY OVERVIEW
  • TABLE 363 SYNEOS HEALTH: PRODUCTS OFFERED
  • TABLE 364 SYNEOS HEALTH: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 365 VERADIGM LLC: COMPANY OVERVIEW
  • TABLE 366 VERADIGM LLC: PRODUCTS OFFERED
  • TABLE 367 VERADIGM LLC: PRODUCT LAUNCHES, JANUARY 2022-JUNE 2025
  • TABLE 368 VERADIGM LLC: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 369 ESO: COMPANY OVERVIEW
  • TABLE 370 ESO: PRODUCTS OFFERED
  • TABLE 371 ESO: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 372 ORDINAL DATA, INC.: COMPANY OVERVIEW
  • TABLE 373 ORDINAL DATA, INC.: PRODUCTS OFFERED
  • TABLE 374 CEDARON MEDICAL: COMPANY OVERVIEW
  • TABLE 375 CEDARON MEDICAL: PRODUCTS OFFERED
  • TABLE 376 FIVOS HEALTH: COMPANY OVERVIEW
  • TABLE 377 FIVOS HEALTH: PRODUCTS OFFERED
  • TABLE 378 FIVOS HEALTH: DEALS, JANUARY 2022-JUNE 2025
  • TABLE 379 ACROSS HEALTHCARE: COMPANY OVERVIEW
  • TABLE 380 ACROSS HEALTHCARE: PRODUCTS OFFERED
  • TABLE 381 ACROSS HEALTHCARE: DEALS, JANUARY 2022-JUNE 2025

List of Figures

  • FIGURE 1 PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION
  • FIGURE 8 PATIENT REGISTRY SOFTWARE MARKET: REVENUE ESTIMATION APPROACH
  • FIGURE 9 BOTTOM-UP APPROACH: END-USER SPENDING ON PATIENT REGISTRY SOFTWARE
  • FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025-2030)
  • FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 12 TOP-DOWN APPROACH
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 19 PATIENT REGISTRY SOFTWARE MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 20 GROWING DEMAND FOR REAL-WORLD EVIDENCE, INTEROPERABILITY, AND REGULATORY COMPLIANCE TO DRIVE MARKET GROWTH
  • FIGURE 21 SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES IN NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE IN 2025
  • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 23 GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD
  • FIGURE 24 PATIENT REGISTRY SOFTWARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 26 PATIENT REGISTRY SOFTWARE MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 PATIENT REGISTRY SOFTWARE MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 PATIENT REGISTRY SOFTWARE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN PATIENT REGISTRY SOFTWARE, 2015-2025
  • FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR "PATIENT REGISTRY SOFTWARE" PATENTS (JANUARY 2015-JUNE 2025)
  • FIGURE 31 MAJOR PATENTS IN PATIENT REGISTRY SOFTWARE MARKET (JANUARY 2015-JUNE 2025)
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 33 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 35 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING PATIENT REGISTRY SOFTWARE ACROSS INDUSTRIES
  • FIGURE 36 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 37 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
  • FIGURE 38 EUROPE: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET, 2020-2024 (USD MILLION)
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET (2024)
  • FIGURE 42 PATIENT REGISTRY SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 43 PATIENT REGISTRY SOFTWARE MARKET: COMPANY FOOTPRINT
  • FIGURE 44 PATIENT REGISTRY SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 45 EV/EBITDA OF KEY VENDORS
  • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 47 PATIENT REGISTRY SOFTWARE MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS
  • FIGURE 48 IBM: COMPANY SNAPSHOT (2024)
  • FIGURE 49 IQVIA HOLDINGS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 HEALTH CATALYST, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 ORACLE: COMPANY SNAPSHOT (2024)
  • FIGURE 52 UNITEDHEALTH GROUP: COMPANY SNAPSHOT (2024)
  • FIGURE 53 CONDUENT INCORPORATED: COMPANY SNAPSHOT (2024)
  • FIGURE 54 ELEKTA: COMPANY SNAPSHOT (2024)
  • FIGURE 55 NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED): COMPANY SNAPSHOT
  • FIGURE 56 DASSAULT SYSTEMES (MEDIDATA): COMPANY SNAPSHOT (2024)
  • FIGURE 57 VERADIGM LLC: COMPANY SNAPSHOT (2022)
目次
Product Code: HIT 3094

The global patient registry software market is expected to reach USD 3.61 billion by 2030 from USD 2.25 billion in 2025, at a CAGR of 9.8%. Healthcare systems are increasingly focused on capturing and analyzing patient data to enhance care quality and meet regulatory requirements. Patient registry software collects disease, procedure, and population data, facilitating clinical research and population health management. These platforms are vital for generating real-world evidence to support drug assessments and value-based care, ultimately reducing healthcare costs and driving market growth.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Use Case, Registry Type, Deployment Model, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Patient Registry Software Market - IMG1

"The direct-to-patient registries segment is expected to witness the highest growth during the forecast period."

The patient registry software market is divided into direct-to-patient and site-based/clinical data registries. Direct-to-patient registries are expected to register the highest CAGR due to increased patient engagement, adoption of digital health tools (like ePRO and mobile apps), demand for real-world evidence from patients, and the rise of decentralized clinical trials that focus on patient-reported outcomes. Virtual platforms simplify data collection, easing the burden on healthcare providers and allowing for better longitudinal follow-up and diverse patient recruitment.

"The medical research & clinical studies segment held the largest share of the patient registry software market, by use case, in 2024."

In 2024, the medical research & clinical studies segment dominated the patient registry software market. This growth is largely driven by the increasing use of real-world data (RWD) and real-world evidence (RWE) for clinical trials and drug development. Patient registry software captures structured and longitudinal patient data, helping researchers analyze outcomes and monitor safety. The rise of personalized medicine and collaborations among life science companies, academic centers, and public health agencies further enhances the need for robust registry infrastructure. The shift toward decentralized trials and post-marketing surveillance also reinforces this segment's leading position.

"North America accounted for the largest share of the patient registry software market in 2024."

In 2024, North America held the largest share of the patient registry software market, driven by strong regulatory frameworks and early digital health adoption. Key players like MRO Corp and ImageTrend enhance competition and innovation. Federal initiatives, such as the US HHS's data modernization and the CDC's focus on chronic disease surveillance, increase the demand for registry platforms. Notably, in February 2025, Veradigm and HealthVerity partnered to integrate cardiovascular and metabolic data with HealthVerity's privacy-compliant platform, enabling comprehensive research on patient journeys. Additionally, in April 2024, ESO Solutions acquired Logis Solutions to improve data-driven emergency response, enhancing interoperability and patient outcomes. These developments solidify North America's leadership in patient registry software innovation and data integration.

The breakdown of primary participants is listed below:

  • By Company Type: Tier 1 (45%), Tier 2 (30%), and Tier 3 (25%)
  • By Designation: C-level Executives (42%), Directors (31%), and Others (27%)
  • By Region: North America (35%), Europe (30%), Asia Pacific (25%), the Middle East & Africa (5%), and Latin America (5%)

Key Players in the Patient Registry Software Market

The key players in the patient registry software market include IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), Elekta (Sweden), Dassault Systemes (France), EvidentIQ (Dacima Software Inc.) (Germany), MRO (Figmd, Inc.) (US), ImageTrend, Inc. (US), Global Vision Technologies, Inc. (US), Syneos Health (US), Veradigm LLC (US), ESO (US), Ordinal Data, Inc. (US), NEC Corporation (NEC Software Solutions UK Limited) (Japan), Cedaron Medical (US), Fivos Health (US), and Across Health (US).

Research Coverage

The report analyzes the patient registry software market. Its objective is to estimate the market size and future growth potential of various segments, categorized by product, registry type, use case, deployment model, end user, and region. Additionally, the report includes a competitive analysis of the key players in this market, featuring their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help both established companies and new or smaller firms assess the market's current state, enabling them to capture a larger market share. Organizations that purchase this report can utilize one or more of the strategies outlined below to enhance their market positions.

This report provides insights on:

  • Analysis of Key Drivers: Drivers (growing demand for real-world evidence (RWE) and rising incidence of chronic and rare diseases), restraints (high setup and operational costs and limited access in low-resource settings), opportunities [integration with AI and analytics tools and expanding use in decentralized clinical trials (DCTs)], and challenges (inconsistent data quality and completeness and limited workforce expertise) influencing the growth of the patient registry software market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the patient registry software market.
  • Market Development: Comprehensive information on the lucrative emerging markets, products, use cases, registry types, deployment models, end users, and regions.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the patient registry software market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the patient registry software market, such as IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), and Elekta (Sweden).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primary sources
  • 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.3 MARKET SIZE ESTIMATION
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 MARKET SIZING ASSUMPTIONS
    • 2.5.2 OVERALL STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PATIENT REGISTRY SOFTWARE MARKET OVERVIEW
  • 4.2 NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT & REGION
  • 4.3 PATIENT REGISTRY SOFTWARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 PATIENT REGISTRY SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 MARKET DYNAMICS
      • 5.2.1.1 Rising burden of chronic and rare diseases
      • 5.2.1.2 Shift toward value-based and patient-centered care
      • 5.2.1.3 Expansion of real-world evidence (RWE) and post-marketing surveillance needs
      • 5.2.1.4 Increasing use of digital health technologies and interoperable EHRs
      • 5.2.1.5 Government and regulatory incentives for registry implementation
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Shortage of trained and skilled resources
      • 5.2.2.2 High implementation and maintenance costs
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Expansion of population health management and outcomes tracking
      • 5.2.3.2 Rising demand for pregnancy and congenital anomaly registries for maternal-fetal safety monitoring
      • 5.2.3.3 Growing preference for subscription-based deployment models
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Privacy- and data security-related concerns
      • 5.2.4.2 Reluctance to adopt advanced patient registry solutions
      • 5.2.4.3 Limited awareness among healthcare stakeholders
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 INDUSTRY TRENDS
    • 5.4.1 STRENGTHENED FUNDING FOR PATIENT-CENTERED RESEARCH AND RARE DISEASE REGISTRIES
    • 5.4.2 RISE IN AUTOMATED DATA ENTRY AND REGISTRY INTELLIGENCE
    • 5.4.3 CLOUD-BASED REGISTRIES AND DECENTRALIZED ACCESS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Electronic data capture (EDC) systems
      • 5.7.1.2 Cloud computing & SaaS architecture
      • 5.7.1.3 Data privacy & security technologies
    • 5.7.2 COMPLEMENTARY TECHNOLOGIES
      • 5.7.2.1 Electronic health record (EHR) systems
      • 5.7.2.2 Clinical trial management systems (CTMS)
    • 5.7.3 ADJACENT TECHNOLOGIES
      • 5.7.3.1 Digital therapeutics (DTx) platforms
      • 5.7.3.2 Wearable devices & remote monitoring tools
      • 5.7.3.3 Blockchain for health data management
  • 5.8 REGULATORY ANALYSIS
    • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.8.2 REGULATORY LANDSCAPE
      • 5.8.2.1 North America
      • 5.8.2.2 Europe
      • 5.8.2.3 Asia Pacific
      • 5.8.2.4 Middle East & Africa
      • 5.8.2.5 Latin America
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE COST OF PATIENT REGISTRY SOFTWARE, BY END USER (2024)
    • 5.9.2 INDICATIVE PRICE OF PATIENT REGISTRY SOFTWARE, BY REGION (2024)
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.10.2 BARGAINING POWER OF BUYERS
    • 5.10.3 THREAT OF SUBSTITUTES
    • 5.10.4 THREAT OF NEW ENTRANTS
    • 5.10.5 BARGAINING POWER OF SUPPLIERS
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS FOR PATIENT REGISTRY SOFTWARE MARKET
    • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PATIENT REGISTRY SOFTWARE
    • 5.11.3 MAJOR PATENTS IN PATIENT REGISTRY SOFTWARE MARKET
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 KEY BUYING CRITERIA
  • 5.13 END-USER ANALYSIS
    • 5.13.1 UNMET NEEDS
    • 5.13.2 END-USER EXPECTATIONS
  • 5.14 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.15 CASE STUDY ANALYSIS
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 BUSINESS MODEL ANALYSIS
  • 5.18 IMPACT OF AI/GEN AI ON PATIENT REGISTRY SOFTWARE MARKET
    • 5.18.1 TOP USE CASES & MARKET POTENTIAL
    • 5.18.2 KEY USE CASES
    • 5.18.3 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
      • 5.18.3.1 Case study: AI-powered data summarization improves registry utilization efficiency
    • 5.18.4 ELECTRONIC HEALTH RECORD (EHR) MARKET
    • 5.18.5 REAL WORLD EVIDENCE (RWE) MARKET
    • 5.18.6 USER READINESS AND IMPACT ASSESSMENT
      • 5.18.6.1 User readiness
        • 5.18.6.1.1 Hospitals & research networks
      • 5.18.6.2 Impact assessment
        • 5.18.6.2.1 Hospitals & academic research institutes
          • 5.18.6.2.1.1 Implementation
          • 5.18.6.2.1.2 Impact
  • 5.19 IMPACT OF 2025 US TARIFFS ON PATIENT REGISTRY SOFTWARE MARKET
    • 5.19.1 INTRODUCTION
    • 5.19.2 KEY TARIFF RATES
    • 5.19.3 PRICE IMPACT ANALYSIS
      • 5.19.3.1 Cloud hosting infrastructure
      • 5.19.3.2 AI & analytics modules
      • 5.19.3.3 Offshore development & support services
    • 5.19.4 IMPACT ON COUNTRY/REGION
      • 5.19.4.1 US
      • 5.19.4.2 Europe
      • 5.19.4.3 Asia Pacific
    • 5.19.5 IMPACT ON END-USE INDUSTRIES
      • 5.19.5.1 For-profit registries
      • 5.19.5.2 Nonprofit registries
      • 5.19.5.3 Government & third-party administrators
      • 5.19.5.4 Others

6 PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE

  • 6.1 INTRODUCTION
  • 6.2 DISEASE REGISTRIES
    • 6.2.1 DIABETES REGISTRIES
      • 6.2.1.1 Need to monitor disease prevalence, treatment adherence, and long-term complications to boost adoption
    • 6.2.2 CARDIOVASCULAR REGISTRIES
      • 6.2.2.1 Ability of cardiovascular registries to enable healthcare systems to benchmark care quality and identify treatment gaps to boost growth
    • 6.2.3 CANCER REGISTRIES
      • 6.2.3.1 Critical tools for understanding cancer epidemiology and evaluating screening programs to drive market
    • 6.2.4 RARE DISEASE REGISTRIES
      • 6.2.4.1 Essential tools for advancing knowledge about rare diseases to support market growth
    • 6.2.5 ASTHMA REGISTRIES
      • 6.2.5.1 Improving asthma management and reducing exacerbations to fuel growth
    • 6.2.6 CHRONIC KIDNEY REGISTRIES
      • 6.2.6.1 Ability of registries to collect detailed data on disease progression, lab results, and treatment adherence to boost adoption
    • 6.2.7 ORTHOPEDIC REGISTRIES
      • 6.2.7.1 Ability to monitor implant performance, surgical outcomes, and complication rates to drive growth
    • 6.2.8 IMMUNIZATION REGISTRIES
      • 6.2.8.1 Strengthening vaccine coverage and safety monitoring to propel market
    • 6.2.9 BIRTH DEFECT REGISTRIES
      • 6.2.9.1 Need to track and prevent congenital anomalies through birth defect registries to propel market growth
    • 6.2.10 OTHER DISEASE REGISTRIES
  • 6.3 PRODUCT REGISTRIES
    • 6.3.1 MEDICAL DEVICE REGISTRIES
      • 6.3.1.1 Ability of these registries to enhance safety, performance monitoring, and regulatory compliance to boost growth
    • 6.3.2 DRUG REGISTRIES
      • 6.3.2.1 Ability to support long-term safety, real-world evidence, and optimal therapy use to propel growth

7 PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
  • 7.2 DIRECT-TO-PATIENT (PATIENT-RECORDED) REGISTRIES
    • 7.2.1 INCREASING PATIENT ENGAGEMENT AND DEMAND FOR SELF-REPORTED DATA TO BOOST MARKET GROWTH
  • 7.3 SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES
    • 7.3.1 GROWING NEED FOR ACCURATE, CLINICIAN-VERIFIED DATA AND SEAMLESS EHR INTEGRATION TO SUPPORT GROWTH

8 PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE

  • 8.1 INTRODUCTION
  • 8.2 MEDICAL RESEARCH & CLINICAL STUDIES
    • 8.2.1 GROWING NEED TO LEVERAGE REGISTRIES TO ENHANCE REAL-WORLD EVIDENCE AND CLINICAL TRIAL EFFICIENCY TO FUEL GROWTH
  • 8.3 QUALITY IMPROVEMENT
    • 8.3.1 ADVANTAGES SUCH AS EVIDENCE-BASED PRACTICE AND PERFORMANCE BENCHMARKING TO DRIVE SEGMENTAL GROWTH
  • 8.4 PATIENT CARE MANAGEMENT
    • 8.4.1 ABILITY TO EMPOWER PROACTIVE CHRONIC DISEASE MANAGEMENT THROUGH CENTRALIZED REGISTRIES TO SUPPORT GROWTH
  • 8.5 POPULATION HEALTH
    • 8.5.1 EXPANDING ROLE OF PATIENT MANAGEMENT SYSTEMS IN DRIVING DIGITAL TRANSFORMATION TO CONTRIBUTE TO GROWTH
  • 8.6 POINT-OF-CARE SUPPORT
    • 8.6.1 NEED FOR PERSONALIZED TREATMENT PLANS AND SHARED DECISION-MAKING TO DRIVE EFFICIENCY AND QUALITY IN HEALTHCARE
  • 8.7 PUBLIC HEALTH SURVEILLANCE
    • 8.7.1 ABILITY OF REGISTRIES TO ENHANCE PREPAREDNESS AND RESPONSE CAPABILITIES TO DRIVE SEGMENTAL GROWTH
  • 8.8 PATIENT SELF-CARE
    • 8.8.1 GROWING EMPHASIS ON PATIENT EMPOWERMENT AND SELF-MANAGEMENT TO PROPEL GROWTH
  • 8.9 PATIENT ENGAGEMENT
    • 8.9.1 ADVANTAGES SUCH AS BETTER DATA ACCURACY AND MORE MEANINGFUL OUTCOMES TO BOOST GROWTH
  • 8.10 OTHER USE CASES

9 PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT

  • 9.1 INTRODUCTION
  • 9.2 ON-PREMISE MODELS
    • 9.2.1 GROWING DEMAND FOR SECURITY, CONTROL, AND COMPLIANCE TO DRIVE MARKET GROWTH
  • 9.3 CLOUD-BASED MODELS
    • 9.3.1 SCALABILITY, INTEROPERABILITY, AND COST-EFFECTIVENESS OF CLOUD-BASED MODELS TO DRIVE GROWTH

10 PATIENT REGISTRY SOFTWARE MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 FOR-PROFIT REGISTRIES
    • 10.2.1 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES
      • 10.2.1.1 Need for robust evidence generation, enhanced patient safety, and competitive differentiation to drive adoption
    • 10.2.2 HEALTHCARE PAYERS
      • 10.2.2.1 Need to improve population health management, control costs, and assess treatment value to drive demand
    • 10.2.3 HEALTHCARE PROVIDERS
      • 10.2.3.1 Hospitals
        • 10.2.3.1.1 Ability of registries to help hospitals collect detailed data on procedures, outcomes, and complications to boost market
      • 10.2.3.2 Clinics & outpatient settings
        • 10.2.3.2.1 Ability of registries to enable data-driven decision-making and streamlined documentation to drive demand
      • 10.2.3.3 Other healthcare providers
  • 10.3 NONPROFIT REGISTRIES
    • 10.3.1 MEDICAL SPECIALTY SOCIETIES
      • 10.3.1.1 Advantages such as defined best practices and improved care delivery to propel growth
    • 10.3.2 PATIENT ORGANIZATIONS
      • 10.3.2.1 Importance of facilitating clinical trial recruitment and fostering collaboration with researchers to support growth
  • 10.4 GOVERNMENT & THIRD-PARTY ADMINISTRATORS
    • 10.4.1 ABILITY OF GOVERNMENT-RUN REGISTRIES TO EVALUATE SUCCESS OF HEALTHCARE INITIATIVES TO FUEL MARKET
  • 10.5 OTHER END USERS

11 PATIENT REGISTRY SOFTWARE MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 US to dominate global market for patient registry software
    • 11.2.3 CANADA
      • 11.2.3.1 Government investment, collaborative initiatives, and strong push to standardize rare disease registries to drive growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 UK
      • 11.3.2.1 Growing incidence of cancer to drive market growth
    • 11.3.3 GERMANY
      • 11.3.3.1 National rollout of e-patient files and rare disease registries to strengthen patient care and research
    • 11.3.4 FRANCE
      • 11.3.4.1 Growing patient registry adoption with national data platforms and rare disease initiatives to support market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Growing number of national networks and disease-specific registries to drive growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Growing need to address rising chronic and cardiovascular disease prevalence to drive adoption
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 JAPAN
      • 11.4.2.1 Japan's aging population and advanced digital strategies to drive growth in patient registry software market
    • 11.4.3 CHINA
      • 11.4.3.1 Robust national registries and expanding pharmaceutical approvals to drive patient registry software market
    • 11.4.4 INDIA
      • 11.4.4.1 Digital health advances to boost India's patient registry software market
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Brazil to dominate patient registry software market in Latin America
    • 11.5.3 MEXICO
      • 11.5.3.1 Increase in focus of digital health to boost market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Rising healthcare investments to fuel uptake
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET
  • 12.3 REVENUE ANALYSIS, 2020-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Product footprint
      • 12.5.5.4 Use case footprint
      • 12.5.5.5 Registry type footprint
      • 12.5.5.6 Deployment footprint
      • 12.5.5.7 End-user footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.6.5.1 Detailed list of key startups/SMEs
      • 12.6.5.2 Competitive benchmarking of startups/Smes
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/SOFTWARE COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES, APPROVALS, UPGRADES, AND ENHANCEMENTS
    • 12.9.2 DEALS
    • 12.9.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 IBM
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product enhancements
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 IQVIA HOLDINGS INC.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 HEALTH CATALYST, INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product approvals
        • 13.1.3.3.2 Deals
        • 13.1.3.3.3 Other developments
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 ORACLE
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 UNITEDHEALTH GROUP
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Right to win
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 CONDUENT INCORPORATED
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Deals
    • 13.1.7 ELEKTA
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Deals
    • 13.1.8 NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED)
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
    • 13.1.9 DASSAULT SYSTEMES (MEDIDATA)
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches
        • 13.1.9.3.2 Deals
    • 13.1.10 EVIDENTIQ (DACIMA SOFTWARE INC.)
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 DEALS
    • 13.1.11 MRO (FIGMD, INC.)
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Deals
        • 13.1.11.3.2 Other developments
    • 13.1.12 IMAGETREND
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product upgrades
        • 13.1.12.3.2 Deals
    • 13.1.13 GLOBAL VISION TECHNOLOGIES, INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Other developments
    • 13.1.14 SYNEOS HEALTH
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Deals
    • 13.1.15 VERADIGM LLC
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product launches
        • 13.1.15.3.2 Deals
    • 13.1.16 ESO
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Deals
    • 13.1.17 ORDINAL DATA INC.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products offered
    • 13.1.18 CEDARON MEDICAL
      • 13.1.18.1 Business overview
      • 13.1.18.2 Products offered
    • 13.1.19 FIVOS HEALTH
      • 13.1.19.1 Business overview
      • 13.1.19.2 Products offered
      • 13.1.19.3 Recent developments
        • 13.1.19.3.1 Deals
    • 13.1.20 ACROSS HEALTHCARE
      • 13.1.20.1 Business overview
      • 13.1.20.2 Products offered
      • 13.1.20.3 Recent developments
        • 13.1.20.3.1 Deals
  • 13.2 OTHER PLAYERS
    • 13.2.1 VERANA HEALTH
    • 13.2.2 PULSE INFOFRAME INC.
    • 13.2.3 AMPLITUDE CLINICAL OUTCOMES
    • 13.2.4 NPHASE, INC. (REDCAP CLOUD)
    • 13.2.5 OM1

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS